Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer.
The main questions it aims to answer are:
\- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles?
Participants will:
* Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment.
* Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.
Phase:
NA
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Korea Health Industry Development Institute Seoul National University Boramae Hospital Seoul National University Bundang Hospital